Is FRMM or JSPR more profitable?

Forum Markets' return on equity of -242.09% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Jasper Therapeutics N/A -613.51% -162.52%

Do analysts recommend THAR or JSPR?

Jasper Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 1,411.34%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has preferable earnings and valuation, THAR or JSPR?

Tharimmune is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is THAR or JSPR more profitable?

Tharimmune's return on equity of -588.45% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Jasper Therapeutics N/A -613.51% -162.52%

Does the media prefer ATRA or JSPR?

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.00 beat Atara Biotherapeutics' score of -0.07 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is JSPR or IBIO more profitable?

iBio's return on equity of -53.86% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Jasper Therapeutics N/A -613.51% -162.52% iBio N/A -53.86% -46.48%

Does the media refer more to JSPR or IBIO?

In the previous week, iBio had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Jasper Therapeutics. iBio's average media sentiment score of 0.60 beat Jasper Therapeutics' score of 0.00 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ENLV or JSPR?

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is ENLV or JSPR more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Jasper Therapeutics N/A -613.51% -162.52%

Does the media favor ENLV or JSPR?

In the previous week, Enlivex Therapeutics had 8 more articles in the media than Jasper Therapeutics. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 2 mentions for Jasper Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.62 beat Jasper Therapeutics' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Jasper Therapeutics (JSPR) Competitors

$0.79 +0.08 (+11.91%)

As of 02:43 PM Eastern

Compare

JSPR vs. FRMM, THAR, ATRA, IBIO, and ENLV

Should you buy Jasper Therapeutics stock or one of its competitors? MarketBeat compares Jasper Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jasper Therapeutics include Forum Markets (FRMM), Tharimmune (THAR), Atara Biotherapeutics (ATRA), iBio (IBIO), and Enlivex Therapeutics (ENLV).

How does Jasper Therapeutics compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and Jasper Therapeutics (NASDAQ:JSPR) are related small-cap companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Forum Markets' return on equity of -242.09% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Jasper Therapeutics	N/A	-613.51%	-162.52%

4.1% of Forum Markets shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 25.2% of Forum Markets shares are owned by company insiders. Comparatively, 2.3% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Forum Markets has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Forum Markets. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Forum Markets. Forum Markets' average media sentiment score of 0.00 equaled Jasper Therapeutics'average media sentiment score.

Company	Overall Sentiment
Forum Markets	Neutral
Jasper Therapeutics	Neutral

Jasper Therapeutics has lower revenue, but higher earnings than Forum Markets. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	12.80	-$450.52M	-$36.07	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Forum Markets currently has a consensus target price of $10.00, suggesting a potential upside of 59.74%. Jasper Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 1,411.34%. Given Jasper Therapeutics' higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Forum Markets and Jasper Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Jasper Therapeutics (NASDAQ:JSPR) are related small-cap companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 2.3% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Jasper Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 1,411.34%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Tharimmune's return on equity of -588.45% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.02, indicating that its share price is 202% more volatile than the broader market.

In the previous week, Jasper Therapeutics had 2 more articles in the media than Tharimmune. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Tharimmune. Tharimmune's average media sentiment score of 0.00 equaled Jasper Therapeutics'average media sentiment score.

Company	Overall Sentiment
Tharimmune	Neutral
Jasper Therapeutics	Neutral

Tharimmune is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Summary

Jasper Therapeutics beats Tharimmune on 9 of the 12 factors compared between the two stocks.

How does Jasper Therapeutics compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Atara Biotherapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.02, suggesting that its share price is 202% more volatile than the broader market.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 2.3% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Jasper Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$23.14M	3.35	$32.69M	-$0.67	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

Atara Biotherapeutics currently has a consensus price target of $9.50, indicating a potential upside of 10.47%. Jasper Therapeutics has a consensus price target of $12.00, indicating a potential upside of 1,411.34%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Jasper Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Jasper Therapeutics	N/A	-613.51%	-162.52%

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.00 beat Atara Biotherapeutics' score of -0.07 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Jasper Therapeutics beats Atara Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Jasper Therapeutics compare to iBio?

Jasper Therapeutics (NASDAQ:JSPR) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, iBio had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for iBio and 2 mentions for Jasper Therapeutics. iBio's average media sentiment score of 0.60 beat Jasper Therapeutics' score of 0.00 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio's return on equity of -53.86% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-613.51%	-162.52%
iBio	N/A	-53.86%	-46.48%

iBio has higher revenue and earnings than Jasper Therapeutics. iBio is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A
iBio	$400K	174.50	-$18.38M	-$0.58	N/A

Jasper Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 1,411.34%. iBio has a consensus target price of $5.00, suggesting a potential upside of 255.87%. Given Jasper Therapeutics' higher possible upside, equities analysts plainly believe Jasper Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 2.3% of Jasper Therapeutics shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Jasper Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the broader market. Comparatively, iBio has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Summary

iBio beats Jasper Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Jasper Therapeutics compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Enlivex Therapeutics has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the broader market.

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 2.3% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Enlivex Therapeutics had 8 more articles in the media than Jasper Therapeutics. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 2 mentions for Jasper Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.62 beat Jasper Therapeutics' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enlivex Therapeutics' return on equity of 248.08% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Jasper Therapeutics	N/A	-613.51%	-162.52%

Enlivex Therapeutics currently has a consensus target price of $247.50, suggesting a potential upside of 12,400.00%. Jasper Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 1,411.34%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Jasper Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Enlivex Therapeutics beats Jasper Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JSPR vs. The Competition

Export

Metric	Jasper Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$22.23M	$3.71B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.25	9.08	269.95	24.78
Price / Sales	N/A	1,267.38	650.49	107.95
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	5.29	17.64	11.25	6.43
Net Income	-$75.80M	-$13.25M	$3.45B	$347.27M
7 Day Performance	30.96%	5.21%	3.49%	2.53%
1 Month Performance	37.01%	-1.94%	-0.66%	-1.03%
1 Year Performance	-67.59%	60.76%	77.20%	23.28%

Jasper Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JSPR Jasper Therapeutics	2.4825 of 5 stars	$0.79 +11.9%	$12.00 +1,411.3%	-71.0%	$22.23M	N/A	N/A	20	Upcoming Earnings Gap Up
FRMM Forum Markets	2.9334 of 5 stars	$5.54 -3.3%	$10.00 +80.5%	N/A	$76.73M	$6.55M	N/A	7	Gap Down
THAR Tharimmune	N/A	$1.94 -5.8%	N/A	+51.5%	$73.20M	N/A	N/A	2	Positive News
ATRA Atara Biotherapeutics	1.2348 of 5 stars	$7.71 -2.4%	$9.50 +23.2%	-22.8%	$71.18M	$120.77M	N/A	330	News Coverage Analyst Downgrade
IBIO iBio	2.5299 of 5 stars	$1.45 +1.4%	$5.00 +244.8%	N/A	$71.04M	$400K	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JSPR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jasper Therapeutics (JSPR) Competitors

JSPR vs. FRMM, THAR, ATRA, IBIO, and ENLV

How does Jasper Therapeutics compare to Forum Markets?

Summary

How does Jasper Therapeutics compare to Tharimmune?

Summary

How does Jasper Therapeutics compare to Atara Biotherapeutics?

Summary

How does Jasper Therapeutics compare to iBio?

Summary

How does Jasper Therapeutics compare to Enlivex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jasper Therapeutics (JSPR) Competitors

JSPR vs. FRMM, THAR, ATRA, IBIO, and ENLV

How does Jasper Therapeutics compare to Forum Markets?

Is FRMM or JSPR more profitable?

Do insiders & institutionals hold more shares of FRMM or JSPR?

Which has more volatility & risk, FRMM or JSPR?

Does the media favor FRMM or JSPR?

Which has preferable valuation and earnings, FRMM or JSPR?

Do analysts rate FRMM or JSPR?

Summary

How does Jasper Therapeutics compare to Tharimmune?

Do institutionals and insiders have more ownership in THAR or JSPR?

Do analysts recommend THAR or JSPR?

Is THAR or JSPR more profitable?

Which has more volatility & risk, THAR or JSPR?

Does the media favor THAR or JSPR?

Which has preferable earnings and valuation, THAR or JSPR?

Summary

How does Jasper Therapeutics compare to Atara Biotherapeutics?

Which has more volatility & risk, ATRA or JSPR?

Do insiders & institutionals hold more shares of ATRA or JSPR?

Which has stronger valuation and earnings, ATRA or JSPR?

Do analysts rate ATRA or JSPR?

Is ATRA or JSPR more profitable?

Does the media prefer ATRA or JSPR?

Summary

How does Jasper Therapeutics compare to iBio?

Does the media refer more to JSPR or IBIO?

Is JSPR or IBIO more profitable?

Which has preferable valuation & earnings, JSPR or IBIO?

Do analysts recommend JSPR or IBIO?

Do insiders and institutionals have more ownership in JSPR or IBIO?

Which has more risk and volatility, JSPR or IBIO?

Summary

How does Jasper Therapeutics compare to Enlivex Therapeutics?

Which has more risk & volatility, ENLV or JSPR?

Which has preferable earnings & valuation, ENLV or JSPR?

Do institutionals and insiders hold more shares of ENLV or JSPR?

Does the media favor ENLV or JSPR?

Is ENLV or JSPR more profitable?

Do analysts recommend ENLV or JSPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR vs. The Competition

Jasper Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools